

**Zeposia (ozanimod)**  
**Prior Authorization Request Form**  
**Caterpillar Prescription Drug Benefit**  
Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

**URGENT**

MEMBER INFORMATION		
<b>LAST NAME:</b>	<b>FIRST NAME:</b>	
<b>PHONE NUMBER:</b>	<b>DATE OF BIRTH:</b>	
<b>STREET ADDRESS:</b>		
<b>CITY:</b>	<b>STATE:</b>	<b>ZIP CODE:</b>
<b>PATIENT INSURANCE ID NUMBER:</b>		

**MALE**     **FEMALE**    **HEIGHT (IN/CM):** \_\_\_\_\_    **WEIGHT (LB/KG):** \_\_\_\_\_

**ALLERGIES:** \_\_\_\_\_

If you are not the patient or the prescriber, you will need to submit a PHI Disclosure Authorization form with this request which can be found at the following link: [primetherapeutics.com/NOPP](http://primetherapeutics.com/NOPP)

**PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):** \_\_\_\_\_

**AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:** \_\_\_\_\_

PRESCRIBER INFORMATION		
<b>LAST NAME:</b>	<b>FIRST NAME:</b>	
<b>PRESCRIBER SPECIALTY:</b>	<b>EMAIL ADDRESS:</b>	
<b>NPI NUMBER:</b>	<b>DEA NUMBER:</b>	
<b>PHONE NUMBER:</b>	<b>FAX NUMBER:</b>	
<b>STREET ADDRESS:</b>		
<b>CITY:</b>	<b>STATE:</b>	<b>ZIP CODE:</b>
<b>REQUESTER (IF DIFFERENT THAN PRESCRIBER):</b>	<b>OFFICE CONTACT PERSON:</b>	

*Continued next page*

**Zeposia (ozanimod)**  
**Prior Authorization Request Form**  
**Caterpillar Prescription Drug Benefit**  
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

**MEDICATION OR MEDICAL DISPENSING INFORMATION**

**MEDICATION NAME:** \_\_\_\_\_

<b>DOSE/STRENGTH:</b>	<b>FREQUENCY:</b>	<b>LENGTH OF THERAPY/REFILLS:</b>	<b>QUANTITY:</b>
-----------------------	-------------------	-----------------------------------	------------------

**NEW THERAPY**     **RENEWAL**      IF RENEWAL, DATE THERAPY INITIATED: \_\_\_\_\_  
 DURATION OF THERAPY (SPECIFIC DATES): \_\_\_\_\_

**1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?**  
 **YES (IF YES, COMPLETE BELOW)**     **NO**

Medication/Therapy (Specify Drug Name And Dosage):	Duration Of Therapy (Specify Dates):	Response/Reason For Failure/Allergy:

**2. LIST DIAGNOSES:** \_\_\_\_\_ **ICD-10:** \_\_\_\_\_

<input type="checkbox"/> Clinically Isolated Syndrome (CIS) <input type="checkbox"/> Relapsing Remitting Multiple Sclerosis (RRMS) <input type="checkbox"/> Secondary Progressive Multiple Sclerosis (SPMS) <input type="checkbox"/> Ulcerative Colitis (UC) <input type="checkbox"/> Other diagnosis: _____ <div style="text-align: right;">ICD-10 CODE(S): _____</div>	
---	--

**3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.**

**Clinical Information:**

Is drug going to be used in conjunction with a clinical trial?     Yes     No

**Initial Request for Multiple Sclerosis:**

Is the prescriber a neurologist?     Yes     No

Has patient had a 3 month trial each of at least 2 of the following?     Yes     No  
 Please provide documentation.

dimethyl fumarate  
 fingolimod  
 glatiramer acetate  
 teriflunomide



**Zeposia (ozanimod)**  
**Prior Authorization Request Form**  
**Caterpillar Prescription Drug Benefit**  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

**Initial Request for Ulcerative Colitis:**

Is the prescriber a gastroenterologist?  Yes  No

Does patient have Crohn's disease or indeterminate colitis?  Yes  No Please provide documentation.

Has patient tried and failed at least one of the following three therapies: corticosteroids, azathioprine and/or 6-mercaptopurine?  Yes  No Please submit chart documentation.

Has patient tried and failed at least three months of the biosimilar Humira-adalimumab-aacf?  Yes  No Please submit chart documentation.

Does patient have a absolute contraindication to the biosimilar for Humira-adalimumab-aacf)?  Yes  No Please submit documentation

Has the patient tried and had an inadequate response to a 4- month trial of the biosimilar for Stelara-Otulfu(ustekinumb-aauz)?  Yes  No Please submit documentation.

Does patient have a absolute contraindication to the biosimilar for Stelara-Otulfu(ustekinumb-aauz)?  Yes  No Please submit documentation.

Has patient been previously treated with infliximab and/or vedolizumab(Entyvio)?  Yes  No Please submit documentation with dates of service.

Will patient use requested medication in combination with another biologic response modifier or immunomodulatory agent?  Yes  No

**Renewal Request:**

Is prescriber a neurologist?  Yes  No

Is prescriber a gastroenterologist?  Yes  No

Is patient continuing to have a positive response to therapy?  Yes  No Please submit chart documentation.

Will patient use requested medication in combination with another biologic response modifier or immunomodulatory agent?  Yes  No

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

**Zeposia (ozanimod)**  
**Prior Authorization Request Form**  
**Caterpillar Prescription Drug Benefit**  
Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.**

**ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.**

**Prescriber Signature or Electronic I.D. Verification:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.**

**FAX THIS FORM TO: 800-424-7640**  
**MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program**  
Attn: CP-4201  
P.O. Box 64811  
St. Paul, MN 55164-0811  
**Phone: 877-228-7909**

